Kate Beattie is a commercial barrister at the Victorian bar and a director of the Cassandra Gantner Foundation, an organisation supporting children and young people with severe disabilities. Kate is also the President of Batten Disease Support and Research Association. Kate got involved with the genetic epilepsy community after her youngest son, Tom, was diagnosed with late infantile Batten disease (CLN2), a rare genetic epilepsy, in 2016. Tom was the first Australian to receive a ‘precision medicine’ for the treatment of late infantile Batten disease, which medicine is now listed on the Life Saving Drugs Program in Australia.
Topic for Genetic Epilepsy Conference 2022: A journey towards precision medicine for genetic epilepsy